Coverage

23-Nov-2021

Graham Kelly, CEO and Managing Director of Noxopharm, is passionate about mentoring young scientists.

Read More

28-Sep-2021

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that the US patent office has allowed claims relating to the use of a combination of its Veyonda and radiotherapy, including external beam radiotherapy (EBRT), with the purpose of generating abscopal responses in patients with metastatic prostate cancer.

Read more here

28-Sep-2021

“We see the allowance of this patent application as a major win for the company in our goal of seeing DARRT therapy become a mainstream cancer treatment,” says CEO & MD.

Read here

2-Jul-2021

BiotechDispatch: Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that the US FDA has granted Investigational New Drug (IND) approval to the DARRT-2 study.

Read More here

2-Jul-2021

Proactive: Noxopharm Ltd (ASX:NOX) is set for a very busy six months ahead with news flow expected from its Veyonda® immune-oncology drug that works with the body’s defence mechanisms to fight cancer cells. 

Read More here

11-May-2021

Outsourcing-Pharma: Clinical study shows drug has COVID-19 treatment potential. CEO Dr. Graham Kelly discusses the history of Veyonda, details of the NOXCOVID study and next steps with Jenni Spinner, editor.

Read More here

30-Apr-2021

Global Pharma Update reported, "Australian company Noxopharm has reported interim data from its NOXCOVID trial, which showed that its drug candidate Veyonda provided protection against hyper-inflammation (cytokine storm) in moderate Covid-19 patients"

Read More here

30-Apr-2021

Proactive Investors reported, "Noxopharm welcomes prestigious scientific journal reporting success of Veyonda® as booster of chemotherapy in late-stage cancer patients"

Read more here.